Search results for "Double blind"

showing 10 items of 81 documents

An Acute Dose of Specific Grape and Apple Polyphenols Improves Endurance Performance: A Randomized, Crossover, Double-Blind versus Placebo Controlled…

2017

International audience; Polyphenols are thought to be an interesting ergogenic aid for exercise and recovery. However, most studies regarding the effects of polyphenols investigated several days of supplementations. The present work aimed to study the effects of an acute intake of grape and apple polyphenols on the capacity to maintain intense exercise, here named endurance performance. Forty-eight physically active men (31 ± 6 years) were included in this study. During the two testing sessions, volunteers completed an endurance test at a high percentage of their maximal aerobic power and time to exhaustion was measured. Respiratory and pain parameters were also monitored. The preceding eve…

0301 basic medicineAdultMalemedicine.medical_specialtycyclingEveningRandomizationTime FactorsPlacebo-controlled studylcsh:TX341-641PlaceboArticleDouble blind03 medical and health sciences0302 clinical medicineDouble-Blind Methodmaximal exertion; aerobic; cyclingMedicineHumansVitisAcute dose030109 nutrition & dieteticsNutrition and DieteticsCross-Over StudiesExercise Tolerancebusiness.industryPlant ExtractsPolyphenolsfood and beverages030229 sport sciencesRecovery of FunctionCrossover studyaerobicPolyphenolAnesthesiaFruitMalus[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Physical therapyExercise Test[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Francebusinessmaximal exertionlcsh:Nutrition. Foods and food supplyFood Science
researchProduct

Virgin olive oil enriched with its own phenolic compounds or complemented with thyme improves endothelial function: The potential role of plasmatic f…

2017

The aim of the present study was to assess whether different functional virgin olive oils (FVOOs) with varying phenolic compounds (PC) could protect the plasmatic fat-soluble vitamins, which in turn could improve the endothelial function. In order to select the optimal phenolic dose in the improvement of ischemic reactive hyperemia (IRH), a dose-response study (n = 12, healthy subjects) was performed and the enrichment of 500 mg PC/kg oil was selected. In a 3-week cross-over sustained study (n = 33 hypercholesterolemic subjects), the consumption of 25 mL/day of two phenol-enriched olive oils (one enriched with its own PC and another combined with thyme PC) increased IRH and plasma concentra…

0301 basic medicineLuteinMedicine (miscellaneous)030204 cardiovascular system & hematologyHigh-performance liquid chromatographyFat-soluble vitaminsDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineendothelial functionVirgin olive oilTX341-641Food scienceReactive hyperemiaFunció endotelialCiències de la salutICAM-1030109 nutrition & dieteticsNutrition and DieteticsChromatographyNutrition. Foods and food supplyChemistryRetinolHealth sciencesEndothelial functionThymeCiencias de la saludPhenolic compounds1756-4646Oli d'olivaFat-Soluble Vitaminvirgin olive oilFenolsFood ScienceOlive oil
researchProduct

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in pat…

2017

3539 Background: VEGF-A and ANG-2 have complementary roles in regulation of tumor angiogenesis. Targeting VEGF-A with BEV in combination chemotherapy (CT) in mCRC has proven to increase PFS and OS. ANG-2 is overexpressed and associated with poor outcome of mCRC pts receiving BEVcontaining treatment. Hence, dual blockade of VEGF-A and ANG-2 by the bispecific mAb VAN with standard CT may improve clinical activity in mCRC. Methods: All pts received mFOLFOX-6 and were randomized 1:1 to also receive intravenous VAN 2000 mg every other week (Q2W) (Arm A) or BEV 5 mg/kg Q2W (Arm B). The primary end point was investigator assessed progression-free survival (PFS). Key eligibility criteria included …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerbusiness.industryPhases of clinical researchCombination chemotherapymedicine.diseaseSurgeryDouble blind03 medical and health sciences030104 developmental biologyOncologyFOLFOXVanucizumabInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort

2020

Abstract Objectives To describe: (i) factors associated with rapid and delayed ART initiation; (ii) rates of 12 week virological response; and (iii) virologically controlled retention in care by 1 year from ART initiation according to timing of start in a real-life setting. Methods All individuals in the Icona cohort diagnosed with HIV in 2016–17 who initiated ART were grouped according to the time between HIV diagnosis and ART initiation: Group 1, ≤7 days; Group 2, 8–14 days; Group 3, 15–30 days; Group 4, 31–120 days; and Group 5, >120 days. Multivariable logistic regression models were used to identify factors associated with: (i) the probability of rapid (Group 1) and very delayed…

0301 basic medicinediagnosishivcommunicable diseasesHIV InfectionsLogistic regressionVirological responseCohort Studies0302 clinical medicineRetention in CareMedicinePharmacology (medical)HIV Infection030212 general & internal medicineProspective cohort studycd4 count determination proceduredrugsuppressionViral LoadCD4 Lymphocyte Count; Cohort Studies; Humans; Italy; Viral Load; Anti-HIV Agents; HIV Infections; Retention in CarevirologyInfectious DiseasesItalyblood hiv rnaCohorthiv cd4 count determination procedure communicable diseases incomeitaly diagnosis virology blood hiv rna retention in careincomeitalyViral loadHIV ARTCohort studyHumanMicrobiology (medical)medicine.medical_specialtyAnti-HIV Agentsantiretroviral therapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesHIV viral loadInternal medicineHumansHIV CD4 ARTPharmacologybusiness.industrydouble blindAnti-HIV AgentHIV viral load antiretroviral therapy double blind initiation suppression infectionRetention in care030112 virologyinfectioninitiationCD4 Lymphocyte CountObservational studyCohort Studiebusiness
researchProduct

Randomised double-blind placebo-controlled intervention study on the nutritional efficacy of a food for special medical purposes (FSMP) and a dietary…

2019

ObjectiveTo assess whether the symptoms of veisalgia can be reduced by intense water supply and the intake of antioxidative supplements and plant extracts.MethodsWe performed the world’s largest randomised double-blind placebo-controlled intervention study (214 participants) on the efficacy of a food for special medical purposes (FSMP) against veisalgia symptoms. We analysed the effectiveness of: (1) an FSMP, including distinct plant extracts, vitamins and minerals, and additional (antioxidative) compounds; (2) a dietary supplement only comprising vitamins and minerals and additional (antioxidative) compounds; and (3) a placebo containing only glucose. The study followed the CONSORT (Consol…

0301 basic medicinemedicine.medical_specialtyHealth (social science)NauseaBody waterDietary supplementMedicine (miscellaneous)AlcoholPlaceboDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine1506nutritional treatmentlcsh:RC620-627Original ResearchNutrition and Dieteticsbusiness.industryConsolidated Standards of Reporting TrialsIntervention studieslcsh:Nutritional diseases. Deficiency diseases030104 developmental biologychemistrymedicine.symptombusiness030217 neurology & neurosurgeryBMJ Nutrition, Prevention & Health
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROM…

2019

Background: Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.1 Objectives: To assess the efficacy and safety of seletalisib in patients with PSS. Methods: In this Phase II, double-blind, proof of concept study (NCT02610543), patients with PSS having an EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) score ≥5 were randomised 1:1 to seletalisib once daily or placebo (PBO) in addition to current PSS therapy for 12 weeks. The primary endpoint was change from baseline in ESSDAI at Week 12. The s…

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtyLymphocytic infiltrationbusiness.industryPlaceboPreclinical dataDouble blind03 medical and health sciences030104 developmental biology0302 clinical medicineTolerabilitySeletalisibInternal medicinemedicineIn patientSjogren sbusiness
researchProduct

Erratum: Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of do…

2016

Although higher dietary intakes of magnesium (Mg) seem to correspond to lower diabetes incidence, research concerning Mg supplementation in people with or at risk of diabetes is limited. Thus, we aimed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in participants with diabetes or at high risk of diabetes compared with placebo. A literature search in PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov without language restriction, was undertaken. Eligible studies were randomized controlled trials (RCTs) investigating the effect of oral Mg supplementation vs placebo in patients with diabetes or at h…

AdultBlood GlucoseMale0301 basic medicinemedicine.medical_specialtyCalorieMagnesium supplementationMedicine (miscellaneous)030209 endocrinology & metabolismCarbohydrate metabolismlaw.inventionDouble blind03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansMagnesiumAgedRandomized Controlled Trials as TopicGlucose tolerance test030109 nutrition & dieteticsNutrition and Dieteticsmedicine.diagnostic_testbusiness.industryMedicine (all)Medicine (miscellaneous); Medicine (all); Nutrition and DieteticsFastingGlucose Tolerance TestMiddle Agedmedicine.diseaseObesityEndocrinologyMeta-analysisDietary Supplementsmagnesium Nutrition diabetes Dietetics glucose metabolismFemalebusinessBody mass indexEuropean Journal of Clinical Nutrition
researchProduct

Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR ima…

2011

To intraindividually compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast material-enhanced breast magnetic resonance (MR) imaging by using a prospective, multicenter double-blind, randomized protocol.Institutional review board approval and patient informed consent were obtained. One hundred sixty-two women (mean age, 52.8 years ± 12.3 [standard deviation]) enrolled at 17 sites in Europe and China between July 2007 and May 2009 underwent at least one breast MR imaging examination at 1.5 T by using three-dimensional spoiled gradient-echo sequences. Of these, 151 women received both contrast agents in randomized order in otherwise identical examinatio…

AdultGadolinium DTPAChinaContrast MediaBreast NeoplasmsSensitivity and Specificitylaw.inventionDouble blindbreast neoplasm contrast media MRIBreast cancerMegluminebreast neoplasmRandomized controlled trialDouble-Blind MethodlawPredictive Value of TestsImage Interpretation Computer-AssistedmedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyGADOBENATE DIMEGLUMINEAgedAged 80 and overChi-Square DistributionCross-Over Studiesbusiness.industryMiddle Agedmedicine.diseaseMr imagingCrossover studyMagnetic Resonance ImagingEuropeFemaleBreast diseaseNuclear medicinebusinessMRIRadiology
researchProduct

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct